Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 4/20 | 0.56 |
| ▸ | CTSS | P25774 | 4/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 3/20 | 0.54 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
| ▸ | ELANE | P08246 | 1/20 | 0.51 |
| ▸ | ECE1 | P42892 | 2/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20876819 | 1.00 | CTSL (0.56) | CTSLCTSSATMCTSBCTSK | |
| Hydrochloric Acid SCHEMBL20854290 | 1.00 | CTSL (0.56) | CTSLCTSSATMCTSBCTSK | |
| Hydrochloric Acid SCHEMBL20854193 | 1.00 | CTSL (0.56) | CTSLCTSSATMCTSBCTSK | |
| SCHEMBL20869899 | 0.99 | CTSL (0.57) | CTSLCTSSATMCTSBCTSK | |
| SCHEMBL20854293 | 0.99 | CTSL (0.57) | CTSLCTSSATMCTSBCTSK | |
| SCHEMBL20854292 | 0.99 | CTSL (0.57) | CTSLCTSSATMCTSBCTSK | |
| Formic Acid SCHEMBL28896986 | 0.93 | CTSL (0.53) | CTSLCTSSATMCTSBCTSK | |
| Formic Acid SCHEMBL28896984 | 0.93 | CTSL (0.53) | CTSLCTSSATMCTSBCTSK | |
| SCHEMBL21890679 | 0.89 | TRPM8 (0.60) | CTSLCTSSATMCTSBCTSK | |
| Isopropylamine SCHEMBL10558459 | 0.89 | CTSL (0.59) | CTSLCTSSATMCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339507-A1 | METHODS OF SYNTHESIZING AZTREONAM DERIVATIVES | ARIXA PHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | US | claimed |
| WO-2020219258-A1 | METHODS OF SYNTHESIZING AZTREONAM DERIVATIVES | ARIXA PHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | WO | claimed |
| EP-3676247-B1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS INC (US) | 2023-03-08 | — | — | EP | disclosed |
| US-11565999-B2 | Methods of synthesizing aztreonam derivatives | ARIXA PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210009580-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20200339507-A1 | METHODS OF SYNTHESIZING AZTREONAM DERIVATIVES | ARIXA PHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| WO-2020219258-A1 | METHODS OF SYNTHESIZING AZTREONAM DERIVATIVES | ARIXA PHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| US-10815228-B2 | Aztreonam derivatives and uses thereof | ARIXA PHARMACEUTICALS, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| CN-111448182-A | Aztreonam derivative and application thereof | 阿里萨制药有限公司 | 2020-07-24 | — | — | CN | disclosed |
| US-20190211006-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-10280161-B2 | Aztreonam derivatives and uses thereof | ARIXA PHARMACEUTICALS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20190100516-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-04-04 | — | — | US | disclosed |
| US-20060194847-A1 | Novel 6-substituted 2-aminopyridine derivatives | ASTRAZENECA AB (SE) | 2006-08-31 | — | — | US | disclosed |
| EP-1611099-A1 | NOVEL 6-SUBSTITUTED 2-AMINOPYRIDINE DERIVATIVES | AstraZeneca AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004087665-A1 | NOVEL 6-SUBSTITUTED 2-AMINOPYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280161-B2 | Aztreonam derivatives and uses thereof | MGAM, ABCG2, SI | CA2 4806/4885CTSL 1068/4885CTSS 2631/4885 |
| US-20190211006-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | MGAM, ABCG2, SI | CA2 4806/4885CTSL 1068/4885CTSS 2631/4885 |
| US-20200339507-A1 | METHODS OF SYNTHESIZING AZTREONAM DERIVATIVES | DTYMK, TYMS, TYMP | CA2 4760/4885CTSL 2198/4885CTSS 2420/4885 |
| US-20190100516-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | MGAM, ABCG2, SI | CA2 4806/4885CTSL 1068/4885CTSS 2631/4885 |
| US-10815228-B2 | Aztreonam derivatives and uses thereof | MGAM, ABCG2, SI | CA2 4806/4885CTSL 1068/4885CTSS 2631/4885 |
| US-11565999-B2 | Methods of synthesizing aztreonam derivatives | DTYMK, TYMS, TYMP | CA2 4760/4885CTSL 2198/4885CTSS 2420/4885 |
| US-20210009580-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | MGAM, ABCG2, SI | CA2 4806/4885CTSL 1068/4885CTSS 2631/4885 |
| US-20060194847-A1 | Novel 6-substituted 2-aminopyridine derivatives | NOS1, NOS2, NOS3 | CA2 1338/4885CTSL 1774/4885CTSS 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.